Quantum BioPharma Ltd.
QNTMHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeQuantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. The company carries a $14.4M market cap, placing it firmly in the micro-cap category. The company operates through two segments, Biopharmaceutical Innovation and Strategic Investments.
Market Cap
$14.4M
Beta
0.38
P/E (TTM)
—
P/E (Fwd)
-0.29
EPS (TTM)
$-4.98
EPS (Fwd)
$-7.80
ROE
-621.5%
ROA
-51.8%
Cash
$3.9M
Total Debt
$963,314
Free CF
-$5.0M
52W Change
-83.3%
Annual Financials
Cash vs Debt
Where QNTM stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, QNTM finished 38.05% below its 150-day moving average ($3.89) and 41.22% below its 200-day moving average ($4.10). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is QNTM overbought or oversold?
At the October 20, 2026 close, QNTM's RSI(14) was 10.6, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Quantum BioPharma Ltd. holds $3.9M in cash against $963K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$5.0M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -621.5%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With a beta below 0.7, Quantum BioPharma Ltd. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Quantum BioPharma Ltd.'s trajectory.